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Abstract: Smoking is the leading modifiable risk factor for chronic obstructive pulmonary 
disease (COPD), cardiovascular disease (CVD), and lung cancer. Smoking cessation is the 
only proven way of modifying the natural course of COPD. It is also the most effective way 
of reducing the risk for myocardial infarction and lung cancer. However, the full benefits of 
tobacco treatment may not be realized until many years of abstinence. All patients with COPD, 
regardless of severity, appear to benefit from tobacco treatment. Similarly, patients with recent 
CVD events also benefit from tobacco treatment. The risk of total mortality and rate of recur-
rence of lung cancer is substantially lower in smokers who manage to quit smoking following 
the diagnosis of early stage lung cancer or small cell lung cancer. Together, these data suggest 
that tobacco treatment is effective both as a primary and a secondary intervention in reduc-
ing total morbidity and mortality related to COPD, CVD, and lung cancer. In this paper, we 
  summarize the evidence for tobacco treatment and the methods by which smoking cessation 
can be promoted in smokers with lung disease.
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Introduction
Tobacco smoking is a leading cause of mortality worldwide, killing one in 10 adults 
and causing 5 million deaths annually.1,2 Nearly 3000 people die from tobacco-related 
complications each day. By 2030, if the current smoking trends continue, tobacco will 
be responsible for one in six deaths and account for more than 10 million deaths per 
annum.2 Tobacco also exacts a colossal financial toll, leading to an annual global net 
loss of US$200 billion, owing in large part to loss in productivity and increased use of 
health services.2 Unfortunately, about a third of the entire male adult global population 
are daily smokers. The rates are the highest in East Asia and other parts of the   Western 
Pacific region, where nearly two out of three adult males are smokers.3 One-third of 
all tobacco worldwide is consumed in one country, China, where the estimated smok-
ing rate in men is 67% and in women is 4%. Today, there are close to   300 million 
Chinese smokers, which is more than the entire US population and, collectively, they 
consume an estimated 1.7 trillion cigarettes per year – or 3 million cigarettes per 
minute.3 It is estimated that smoking will eventually kill a third of the young Chinese 
men living today (under the age of 30 years).3 Although smoking rates are falling in 
the   Western world, regrettably they are on the rise in the   developing nations. Nearly 
80% of smoking-related morbidity and mortality are accounted for by three condi-
tions: 1) cardiovascular disease (CVD), which is responsible for ∼40% of all smoking-
related deaths; 2) lung cancer, which accounts for ∼20% of all   smoking-related deaths; International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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and 3) chronic obstructive pulmonary disease (COPD), 
which accounts for another 20% of all smoking-related 
mortality.1 In this paper, we will examine the relationship 
of cigarette smoking to these conditions and determine the 
impact tobacco treatment has in patients who have already 
developed these smoking-related conditions.
General benefits of smoking 
cessation
The benefits of smoking cessation in CVD are almost 
immediate. Within 24 hours of smoking cessation, there are 
significant improvements in blood pressure and heart rate.4 
Within one year of abstinence, the risk of cardiovascular events 
(eg, myocardial infarction [MI] and stroke) is reduced by half 
(compared with continued smoking). Between 5 and 15 years 
post-smoking, the risk of stroke and coronary heart disease is 
“normalized” to that of never smokers.4 On the other hand, 
the benefits of tobacco treatment on the risk of lung cancer 
take much longer to achieve. The risk of lung cancer declines 
steadily following smoking cessation such that after about 
10 years of abstinence, the risk of lung cancer is between 30% 
and 50% of that for continued smokers.5 However, even after 
decades of smoking cessation, the risk of lung cancer may 
never reach that of never smokers. The benefits of tobacco 
treatment to COPD progression are measurable within the first 
year of abstinence and are particularly striking in female smok-
ers who manage to quit smoking.6 After several years of 
smoking cessation, the rate of decline in lung function becomes 
similar to that of never smokers.7 However, because the lung 
function lost during the time the patient smoked is never fully 
recovered and because lung function declines with age (even 
in nonsmokers), COPD patients may develop additional 
symptoms and progress to a higher COPD severity class, even 
after many years of smoking abstinence.8
The benefits of smoking cessation  
in patients with established COPD
The landmark studies evaluating the effect of tobacco treat-
ment on cardiopulmonary health outcomes are summarized 
in Table 1. Although the traditional teaching has been that 
only 10%–15% of smokers develop COPD,9 data from 
large epidemiological studies indicate that the risk is nearly 
50%,10 suggesting that one in two smokers, if they live long 
enough, will eventually develop COPD. In the overall popu-
lation, the population-attributable risk of COPD related to 
smoking is approximately 45%.10,11 However, many of these 
patients never present to physicians’ attention because they 
are asymptomatic or minimally symptomatic.12 Among 
clinically symptomatic patients with COPD, the population-
attributable risk related to smoking is much higher.13
Smoking cessation is the only proven way of slowing 
down disease progression in COPD. One of the landmark 
studies that examined the effects of tobacco treatment on 
COPD progression was the Lung Health Study (LHS).7 
In the LHS, 5887 current smokers with mild to moderate 
COPD (Global initiative for chronic Obstructive Lung 
Disease, GOLD, Stages 1 and 2) were randomized to one of 
three treatment arms: 1) usual care, 2) smoking intervention 
plus the inhaled bronchodilator ipratropium, or 3) smoking 
intervention plus an inhaled placebo and were followed for 
5 years.7 The tobacco treatment consisted of: physician rec-
ommendation against smoking, aggressive smoking cessation 
counseling by a health educator 12 times over a 10-week 
period, and nicotine replacement therapy using nicotine gum 
(Nicorette; Marion Merrell Dow Inc, Kansas City, MO). 
The smokers were followed at 4-month intervals to check 
on their smoking status and to institute relapse treatment 
for those who failed to quit or had relapsed. Smokers who 
relapsed were treated aggressively with the above measures 
and by teaching them coping strategies for relieving stress 
and weight gains. Compliance with smoking cessation was 
determined by self-report and verified by measuring expired 
carbon monoxide (at each visit) and salivary cotinine levels 
(at each annual visit). Cotinine levels greater than 20 ng/mL 
were classified as smokers.14 In those who were taking 
nicotine replacement therapy, exhaled carbon monoxide 
concentrations of greater than 10 ppm were considered as 
smokers (as the use of salivary cotinine levels was not reli-
able in these participants). All participants were followed 
in person annually for 5 years, and during each annual visit, 
spirometry measurements were performed and their health 
service utilization including hospitalizations as well as vital 
status data were captured. Over the 5 years of follow-up, 
22% became sustained quitters (ie, classified as a quitter at all 
five follow-up annual visits) in the two groups that received 
special intervention for tobacco treatment.7 In contrast, only 
5% of the smokers in the usual care arm became sustained 
quitters over the 5 years.7 Interestingly, those who were 
sustained quitters at year 5 remained sustained quitters over 
11 years of follow-up, while those who were continuous 
smokers remained continuous smokers at year 11.15 These 
data highlight the importance of effecting and maintaining 
abstinence over the first few years.
Importantly, in the LHS, smoking cessation was associ-
ated with a slower decline in lung function and reduced risk of 
hospitalization and total mortality. Participants in the special International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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intervention group plus a placebo inhaler, who became sus-
tained quitters, experienced a forced expiratory volume in 
one second (FEV1) decline of only 34 mL/year. In contrast, 
those who continued to smoke experienced an FEV1 decline 
of 63 mL/year.7 Thus, smoking cessation nearly halved the 
rate of descent in FEV1 in patients with mild to moderate 
COPD. Smokers who quit and then took up smoking again 
had FEV1 declines that fell somewhere in between that of 
sustained quitters and continued smokers.7 Interestingly, 
female continued smokers experienced a faster decline in 
lung function compared with male continued smokers for 
the amount of cigarettes they smoked.16 However, female 
smokers experienced larger gains in lung function when they 
stopped smoking compared with male quitters.6 Smokers who 
quit and re-initiated smoking at multiple times experienced 
a slower decline in FEV1 than continued smokers, for the 
same number of cigarettes they smoked.16 Together, these data 
suggest that smoking cessation significantly reduces disease 
progression in mild to moderate COPD and that even having 
multiple relapses is better than continued smoking in terms 
of disease progression. Tobacco treatment is particularly 
important for women, who appear to have increased suscep-
tibility to disease progression with continued smoking but 
also derive larger benefits with smoking cessation compared 
with male smokers.
Tobacco treatment and mortality
During the 5 years of the LHS follow-up, 149 participants 
(representing 2.5% of the cohort) died. The leading cause 
of mortality was lung cancer (representing 38.3% of the 
total deaths), followed by CVD (representing 24.8% of the 
total deaths). Smoking cessation was associated with a 32% 
  reduction in all-cause mortality at 5 years of follow-up.17 
This trend persisted over 14.5 years of follow-up. Sustained 
quitters had a total mortality rate that was 42% lower than 
that of continued smokers and intermittent quitters/smokers 
had a 30% lower mortality rate than that of continued 
smokers.5 The salutary effect of smoking cessation was 
most pronounced on CVD mortality, reducing it by 45%. 
Surprisingly, in this study, smoking cessation did not have 
any significant impact on mortality or hospitalization related 
to lower respiratory tract infection or COPD progression. 
However, in the Multiple Risk Factor Intervention Trial 
(MRFIT),18 intervention consisting of smoking cessation, 
and blood pressure and serum cholesterol treatment, was 
associated with a significant 20% reduction in   mortality 
from respiratory causes.18 Smoking cessation reduces 
  mortality from lung cancer.7 Importantly, the risk of lung 
cancer mortality with smoking is modified by lung function 
(or COPD severity) in men, but less so in women.19 In men, 
continuous smokers have increased risk for lung cancer 
mortality for every category of COPD severity. However, 
in sustained quitters and intermittent smokers, the risk is 
not significantly increased until FEV1 is below 80% of pre-
dicted20   (see   Figure 1). In both men and women, smoking 
cessation reduces deaths from lung cancer by over 50%.5 
However, intermittent quitters/smokers do not experience 
a significant decline in mortality rates from lung cancer.5 
Together, these data indicate that smoking cessation reduces 
total mortality by a third to a half and that the greatest and 
most immediate impact is on CVD endpoints. The survival 
effects on COPD- and lung cancer-related mortality are more 
variable and complex.
Tobacco treatment and hospitalization
Of the 5887 patients studied in the LHS, 754 patients 
(representing 12.8% of the cohort) experienced at least 
one hospitalization during the 5 years of follow-up and 
282 patients (representing 4.8% of the cohort and 37.4% 
of those hospitalized at least once) had two or more 
hospitalizations.17 CVD accounted for 42% of the first and 
48% of the second hospitalizations. Coronary heart disease 
was responsible for 75% of all CVD hospitalizations. In the 
INTERHEART study, current smoking was associated with 
a three-fold increase in the risk for nonfatal acute MI.21 The 
relationship was dose-dependent such that those who smoked 
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Figure 1 The relation of lung function and lung cancer mortality in men according 
to smoking status in the MRFIT Study.20 At all Fev1 values, the risk of lung cancer 
mortality is higher in smokers than in intermittent smokers/quitters and sustained 
quitters. In quitters and intermittent smokers, the risk of lung cancer mortality in 
men rises substantially below Fev1 of 80% of predicted.
Abbreviations: Fev1, forced expiratory volume in one second; MRFIT, Multiple 
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a pack per day or more (20+ cigarettes per day) had a 4.6-
fold increase in the risk compared with never smokers.22 
The relationship was also age-dependent, such that younger 
smokers (50 years of age or younger) had significantly higher 
risk of nonfatal MI than older smokers who smoked the same 
number of cigarettes per day.22 The risk declines with smok-
ing cessation. The greatest decline in risk occurs within the 
first 3 years of smoking abstinence.22 Overall, the population 
attributable risk of acute MI related to cigarette smoking is 
36%,21 making it the single most important modifiable risk 
factor for this endpoint. In comparison, diabetes mellitus 
and hypertension, two other leading modifiable risk factors, 
contribute only 10% and 18%, respectively, to the total 
population-attributable risk of acute MI.21
General benefits of smoking 
cessation in patients with asthma
Patients with asthma also benefit from tobacco treatment as 
smoking cessation is associated with improved lung func-
tion, enhanced quality of life, and decreased reliance on 
rescue inhalers.23,24 Smoking cessation also reduces airway 
inflammation.23,25
Benefits of smoking cessation in patients 
with asthma
Tobacco smoke contains many compounds that are nox-
ious and carcinogenic to the airway. Not surprisingly, the 
prevalence of asthma is higher in current and former smok-
ers compared with never-smokers.26 Regrettably, despite the 
detrimental effects of smoking on asthma, the prevalence 
of smoking in asthmatics is comparable to that in the gen-
eral population.27 The risk of developing asthma is greater 
among current smokers than in ex-smokers or occasional 
smokers, especially amongst females.28 Among asthmatics, 
smoking is associated with increased symptoms,29 more 
frequent exacerbations,30 and emergency department visits,31 
and higher health care costs. Smoking is also associated 
with accelerated decline in lung function32 and increased 
mortality.33
There is another important mechanism by which smoking 
can adversely affect asthmatics. It is now well established 
that the most effective pharmacologic treatment for asthma 
is inhaled corticosteroid.34 Smoking, however, promotes 
corticosteroid-insensitivity and attenuates their effective-
ness35 by possibly downregulating histone deacetylase36 
and enhancing neutrophil-mediated airway inflammation.37 
Together, these effects may make the inflammation in asthma 
less susceptible to corticosteroids .
Smoking is a modifiable risk factor and an important target 
in the treatment of asthma. A study by Chaudhuri and colleagues 
showed significant short-term improvements on lung function 
after smoking cessation.25 A recent study by Jang and colleagues 
showed similar findings.23 Interestingly, in this study, the salu-
tary effects of smoking cessation on lung function were greater 
than that achieved by high-dose oral prednisolone. Smoking 
cessation also led to a reduction in sputum neutrophils. In a 
study by Tonnesen, asthmatic patients who managed to quit 
smoking experienced significant improvements in their qual-
ity of life, daytime symptoms, and bronchial hyper-reactivity. 
They also had decreased reliance on rescue inhalers.24 Together, 
these data indicate that smoking cessation is essential in the 
management of patients with asthma.
Benefits of tobacco treatment  
in patients with established  
lung cancer
In the Western nations, smoking is responsible for 90% of 
all cases of lung cancer.38 The risk of dying from lung cancer 
is 22 times higher in male smokers and 12 times higher in 
female smokers compared with never smokers.4 Smoking 
cessation is associated with improved outcomes even among 
patients diagnosed with lung cancer. A recent meta-analysis 
found that in patients who are diagnosed with early stage 
non–small cell lung cancer (NSCLC), smoking cessation 
reduced total mortality by 66% and the risk of recurrence 
or a second lung primary by 46% compared with continued 
smokers.39 The data were similar in patients with small cell lung 
cancer (SCLC). In patients with established SCLC, smoking 
cessation decreased total mortality by 46% and the risk of a 
recurrence or a second lung primary by 77%.39 Collectively, 
these data suggest that among patients diagnosed with early 
to mid stages of NSCLC and SCLC, smoking cessation is 
still beneficial and prolongs survival and reduces the rate of 
recurrence of tumor and/or second lung primaries.
Smoking cessation in patients  
with established CVD
Smoking cessation improves health outcomes in patients who 
have experienced MI and developed mild left ventricular (LV) 
systolic dysfunction. In Survival and Ventricular Enlargement 
(SAVE), which evaluated 2231 subjects with LV dysfunction 
3–16 days following their MI, smoking cessation at 6-month 
follow-up reduced all-cause mortality by 43%, the risk of 
death or recurrent MI by 32%, and death or heart failure 
hospitalization by 35%.40 In comparison, in the same trial, International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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captopril, an angiotensin-converting-enzyme inhibitor, was 
demonstrated to reduce total mortality by 19%, recurrent 
MI rate by 25%, and heart failure hospitalization rate by 
22%.41 Together, these data indicate the critical importance 
of smoking cessation in promoting good health outcomes in 
patients with previous history of MI.
Side effects of smoking cessation
There are very few side effects of smoking cessation. The 
most common is weight gain.42 In the LHS, the average 
weight gain in the first year following smoking cessation 
was 5 kg for both men and women.42 When expressed as 
percentage of baseline weight, women gained more weight 
than did men. The average weight gain in the first year fol-
lowing smoking cessation was 8% (above baseline weight) 
in women and 6% for men.
Interventions to promote  
smoking cessation?
Most smokers are motivated to quit smoking. In the US and 
UK, nearly three out of four workers intend to quit smoking 
every year, yet fewer than 5% are able to quit successfully 
on their own.43,44
Predictors of smoking cessation
There are some clinical factors that have been associated 
with increased abstinence rate in patients with COPD. 
These include: enrolling in intensive smoking cessation 
programs consisting of repeated counseling sessions and 
pharmacotherapy,7 which increases the odds for smoking 
cessation 4.4-fold; older age; and having smoked a fewer 
number of cigarettes over their lifetime. COPD disease 
severity, on the other hand, is not associated with increased 
rates of smoking cessation.
Public policy
Smoking restrictions in public places, work places, and 
households are a very effective way of promoting abstinence. 
However, despite compelling evidence of efficacy, fewer than 
10% of countries mandate smoke-free bars and restaurants, and 
more than 60 countries have no smoke-free policies whatso-
ever.3 Raising prices on tobacco products is another effective 
means of increasing smoking cessation. There is good evidence 
to indicate that when the price of cigarettes increase by more 
than 10%, the rate of abstinence increases by 3%.3 Complete 
advertising bans on tobacco is also effective, reducing smoking 
rates by 6%.3 Although vitally important, these public health 
measures are not enough for the 20%–25% of adults who are 
addicted to nicotine and continue to smoke. Additional mea-
sures are needed to treat these patients’ addictions.
Nonpharmacologic interventions
Patients who try to quit smoking on their own rarely achieve 
complete abstinence over time. Initially, 25%–50% of patients 
succeed; however, by 3 months, the success rate drops off to 
only 10%–20%, and by 6 months, 95%–97% of those who 
tried are back smoking.45 In general, both pharmacotherapies 
and nonpharmacotherapies are needed to significantly impact 
smoking cessation rates.
Smokers with COPD behave similarly to healthy smokers 
when it comes to smoking cessation. Over 12 months, the 
average complete abstinence rate in the COPD population is 
approximately 1.4%,46 though there is a large variation in the 
rates reported in the literature. However, the addition of inten-
sive counseling sessions increases quit rates to about 6.0%. The 
institution of pharmacotherapy on top of intensive counseling 
doubles the cessation rate to 12.3%.46 Minimal counseling, 
defined as counseling sessions that last less than 90 minutes, 
on the other hand, does not materially affect abstinence rates 
(2.6%).46 The addition of pharmacologic agent to counseling 
is synergistic, resulting in a two- to three-fold increase in the 
rate of smoking cessation compared with usual care, or a 1.8-
fold increase in smoking cessation compared with counseling 
alone.47 The use of nicotine replacement therapy in lieu of an 
antidepressant medication results in similar cessation rates as 
that achieved by antidepressant drugs.
Informing smokers that they have COPD slightly increases 
the rate of smoking cessation.48 However, once patients are 
diagnosed with COPD, showing them their abnormal spirom-
etry data does not enhance smoking cessation rates.49,50 If 
the spirometry data are conveyed in the form of “lung age” 
rather than in liters or as a percent of predicted, patients are 
more likely to understand the severity of their lung function 
impairment and thus more likely to quit smoking.51 Lung 
age is defined as the age of the average person with an FEV1 
equal to the patient. The use of lung age in communicating the 
results of lung function tests of smokers results in a two-fold 
increase in the complete abstinence rate at 12 months com-
pared with the standard approach of using liters or percentage 
of predicted values in communicating abnormal spirometry 
results (13.6% versus 6.4%; P = 0.01).51
Pharmacotherapy to effect  
tobacco treatment
In general, among COPD patients, the use of pharmaco-
therapy is superior to nonpharmacotherapy in effecting International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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complete abstinence rates,52 and disease severity does not 
modify cessation rates. The effectiveness of various pharma-
cotherapies for smoking cessation is shown in Figure 2. In 
general, bupropion and varenicline are more effective than 
nicotine replacement therapy (NRT) (Figure 2) and are more 
cost-effective than NRT (Figure 3).53 Pharmacotherapies 
for smoking cessation are highly cost-effective across all 
age groups (Figure 3).53 The addition of behavior therapy to 
pharmacotherapy alone is not cost-effective.53
NRT
Smokers are addicted to nicotine.54 Cigarettes are an   effective 
means of delivering nicotine quickly to the brainstem where it 
stimulates the release of dopamine via the nicotinic receptors. 
NRT aims to take away the cravings for cigarettes and 
mitigate nicotine withdrawal symptoms by providing steady 
stimulation to the nicotinic receptors and preventing the rapid 
fluctuations in the release of dopamine in the forebrain.53,54 
NRT is safe, because unlike cigarettes NRT does not contain 
thousands of nonnicotine products contained in cigarettes. 
NRT comes in various forms, including as a transdermal 
patch, gum, lozenge, inhaler, sublingual tablet, and nasal 
spray. They have similar efficacy in promoting abstinence, 
increasing the rate two-fold compared with placebo.53 The 
results are similar in patients with COPD. One randomized 
controlled trial found that the use of nicotine sublingual 
tablets resulted in a significantly higher 1-year complete 
abstinence rate compared with placebo (14% versus 5%; odds 
ratio [OR] 2.86; P , 0.0001).52 However, in general, the use 
of NRT for hospitalized patients with smoking-related con-
ditions does not appear to increase smoking cessation rates 
above counseling alone.55,56 The reasons for this observation 
are uncertain.
Bupropion
Antidepressants, in particular bupropion, are commonly 
used to increase smoking cessation rates.57 Bupropion 
is an atypical antidepressant that inhibits the re-uptake 
of norepinephrine and dopamine in the brain. The most 
serious side effects of this medication are seizures, which 
occur very infrequently.57 Accordingly, patients with a 
pre-existing seizure condition should not be prescribed 
this medication. The recommended starting adult dose 
is 150 mg per day for 3 days and then increasing to 
300 mg per day.58 In COPD, bupropion is a very effective 
smoking cessation aid, increasing the 6-month complete 
abstinence rate approximately two-fold compared with 
placebo.59,60 Similar to NRT, the use of bupropion in hos-
pitalized patients with smoking-related conditions does 
not appear to increase smoking cessation rates above that 
achieved by counseling.61,62 Together, these data suggest 
that smokers with COPD at any disease severity can be 
treated with bupropion for 12 weeks with the expectation 
that approximately 15%–20% of these smokers will achieve 
complete abstinence by 6 months without experiencing 
significant side effects from the medications.
varenicline
Varenicline is a nicotinic receptor agonist that binds to 
alpha-4 beta-2 receptor as well as to alpha-3 beta-4, alpha-3 
beta-2, alpha-6, and alpha-7 nicotinic receptors.63 By weakly 
binding to these receptors, it causes an attenuated release of 
dopamine in the forebrain, while at the same time preventing 
the binding of these receptors to nicotine. The usual recom-
mended dosage of varenicline for adults is 0.5 mg once daily 
for 3 days, followed by 0.5 mg twice daily for 4 days, and then 
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1 mg twice daily for the remaining portion of the 12-week 
treatment regimen.63 Common side effects in the general 
population are nausea, abdominal cramps, and sleep disorders 
including nightmares. Although suicidal ideation and major 
depression are very uncommon, varenicline is best avoided in 
patients who have a history of major depression or an anxiety 
disorder.63 The effect of varenicline was recently reported in 
the COPD population. In this trial of patients with mild to 
moderate COPD (average FEV1 of 70% of predicted), the use 
of varenicline for 12 weeks was associated with a complete 
abstinence rate of 42% at 3 months of therapy compared 
with only 9% in the placebo group (OR 8.40; P , 0.0001). 
However, by 52 weeks of follow-up, the rate of abstinence 
decreased to about 19% in the varenicline treated group and 
to 6% in the placebo group (OR 4.04; P , 0.0001).64 Serious 
adverse effects related to this medication were rare, occurring 
in approximately 3% of the patients. However, minor side 
effects such as nausea (occurring in 27% of treated patients), 
and abnormal dreams (occurring in 11% of treated patients), 
and other sleep disturbances (eg, insomnia) were relatively 
common.64
Other respiratory benefits  
of tobacco treatment
Along with lung cancer and COPD, smoking has also been 
associated with nonspecific ground-glass opacification and 
centrilobular nodularity on computed tomography scans of 
the chest, which correspond pathologically to respiratory 
bronchiolitis. Some patients with this condition are symp-
tomatic with coughing and shortness of breath, but many may 
be relatively asymptomatic.65 Physiologically, these patients 
may have normal spirometry but almost have reduced dif-
fusing capacity for carbon monoxide. Both the radiographic 
and physiologic changes may improve significantly   following 
smoking cessation.66 Smoking has also been associated with 
fibrotic lung conditions such as idiopathic pulmonary fibrosis, 
respiratory bronchiolitis-interstitial lung disease (RB-ILD), 
desquamative interstitial pneumonitis, and rheumatoid 
arthritis-associated interstitial lung disease,67 and also with 
Langerhans cell histiocytosis.65 The benefits of smoking 
cessation have not been well studied in these conditions. 
However, most lung transplantation programs across the 
world insist on smoking cessation before considering these 
patients for lung transplant, which can be life-preserving for 
patients with end-stage or severe smoking-related fibrotic 
lung disease.
Conclusion
Smoking is responsible for one in five deaths worldwide. 
Although the prevalence of smoking is declining in the 
Western world, the worldwide prevalence is on the rise, owing 
largely to increasing rates in developing nations. It is estimated 
that one in three Chinese men below the age of 30 years will 
die from smoking-related diseases unless smoking rates dra-
matically decrease over the next few years. In patients with 
established COPD, the benefits of smoking cessation are 
immense, regardless of severity. In mild to moderate COPD, 
smoking cessation reduces the risk of disease progression as 
well as the risk for lung cancer and CVD, which collectively 
are the leading causes of morbidity and mortality in this 
population of patients. In more severe cases, smoking cessa-
tion reduces total mortality. In patients with established CVD, 
smoking cessation is more powerful in reducing the recurrence 
of CVD events and total mortality than any pharmacological 
intervention currently in use. For patients with early NSCLC 
or SCLC, smoking cessation improves survival and attenuates 
the risk of recurrence or development of a second primary lung 
cancer. Together, these data provide a compelling rationale 
Table 1 Seminal studies evaluating the effect of tobacco treatment on cardiopulmonary health outcomes
Study (reference number) Sample size Study findings
The Lung Health Study6,7 5887 In patients with mild to moderate COPD, tobacco treatment was associated with reduced 
disease progression and risk of hospitalization and mortality. Women derived larger benefits 
from smoking cessation than male smokers.
Multiple Risk Factor 
Intervention Trial (MRFIT)18,69
12,866 Smoking cessation reduced mortality from lung cancer.
INTeRHeART study21 29,972 Current smoking is the single most important modifiable risk factor for reducing the risk of 
acute myocardial infarction, increasing the relative risk three-fold compared with nonsmokers.
Survival and ventricular 
enlargement (SAve) study40
2231 In patients with left ventricular dysfunction after a recent acute myocardial infarction, smoking 
cessation reduced mortality, risk of recurrent myocardial infarction, hospitalization from 
congestive heart failure, and death. The benefit of smoking cessation was greater than that 
related to the use of an angiotensin converting enzyme inhibitor.
Abbreviation: COPD, chronic obstructive pulmonary disease.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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for aggressively promoting tobacco treatment through public 
health policy and smoking cessation programs. The use of 
bupropion and varenicline in appropriate patients is cost-
effective in fostering complete abstinence.
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